Laabs Amanda H. 4

What Happened

• Amanda H. Laabs, Chief Product Officer of Medline (MDLN), received multiple equity awards and reclassified holdings primarily on 2025-12-16 (with one award reported 2026-03-05). The filing reports a 251,070 share grant plus several derivative "Incentive Units" and RSU-style awards. The aggregate of the reported line items is about 2,313,255 reported shares/units. Most items show no purchase price or economic value in the filing (values = N/A); one small grant of 25,788 shares on 2026-03-05 is listed at $0.00.

Key Details

• Transaction types: all labeled "A" (award/grant/acquisition); includes direct share grant(s), RSUs, and multiple Incentive Units (derivative interests).
• Reported grant line items (high level): 251,070 shares (12/16/2025); 25,788 shares at $0.00 (03/05/2026); plus incentive-unit entries of 251,070; 1,242,391; 189,352; 132,771; and 220,813 (all 12/16/2025).
• Total reported across the lines: ~2,313,255 shares/units (values largely N/A).
• Vesting/convertibility notes from the filing:
  • Some securities were reclassified prior to the issuer’s IPO (footnote F1) and were previously reported on a Form 3 (Dec 17, 2025).
  • Certain awards are RSUs: 25% vest on June 15, 2026; remaining 75% vest in three equal annual installments beginning March 1, 2027 (F3).
  • Incentive Units are "profit interests" with conversion mechanics and vesting schedules; vested Incentive Units can be converted into Common Units according to a formula, and Common Units may be exchangeable for Class A common stock under an Exchange Agreement (F4–F6).
  • Specific vesting splits for various incentive awards: 80% vested / 20% vests Oct 21, 2026 (F7); 40% vested / remaining 60% in three equal annual installments from Apr 1, 2026 (F8); 20% vested / remaining 80% in four equal annual installments from Mar 29, 2026 (F9); other Incentive Units vest in five equal annual installments beginning Mar 28, 2026 (F10).
  • Class B common shares (where applicable) have no economic value and carry one vote per share; they are tied to Common Units and cancel on exchange for Class A shares (F2).
• Shares owned after the transaction: not specified in the provided excerpt of the Form 4.
• Timeliness: The Form 4 was filed 2026-03-06 for transactions dated 2025-12-16 (and 2026-03-05), indicating the reporting was not timely relative to the transaction dates; some items were already reported on a Form 3 per footnote F1.

Context

• These are awards/grants (not open-market purchases or sales). Awards and incentive units are routine for executives and reflect compensation structure and vesting schedules rather than immediate market bets.
• The Incentive Units are derivative/profit-interest instruments (not simple shares) and convert subject to formulas and vesting; conversion and ultimate economic exposure depend on vesting and the exchange/conversion mechanics described in the footnotes.
• Because most line items list no dollar amount, the filing does not disclose the immediate market value of the grants; check the issuer’s S-1/registration statement and later filings for valuation details.